GO:0004594 pantothenate kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004594 (pantothenate kinase activity) is a molecular function that catalyzes the ATP-dependent phosphorylation of pantothenate (vitamin B5) to 4'-phosphopantothenate, the rate-limiting first step in coenzyme A (CoA) biosynthesis.
• Four human pantothenate kinase genes exist (PANK1-PANK4); PANK1, PANK2 and PANK3 encode catalytically active enzymes, whereas PANK4 is a pseudo-pantothenate kinase with little or no canonical activity.
• Pantothenate kinase activity is essential for CoA supply, which fuels the TCA cycle, fatty acid synthesis and oxidation, and acetyltransferase reactions.
• PANK4 controls skeletal muscle substrate metabolism and lipid synthesis for T-cell proliferation by modulating CoA and glutaminolysis.
• SGLT2 inhibitors activate pantothenate kinase in the human heart, linking this activity to cardiac metabolic regulation.
• Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome, highlighting the physiological importance of pantothenate availability and its phosphorylation.
Description
Pantothenate kinase activity (GO:0004594) is the enzymatic function that transfers a phosphate group from ATP to pantothenate (vitamin B5), producing 4'-phosphopantothenate. This reaction is the first and rate-limiting step in the biosynthesis of coenzyme A (CoA), a central acyl-group carrier and cofactor required for cellular metabolism, including the tricarboxylic acid (TCA) cycle, fatty acid synthesis and oxidation, and numerous acetylation reactions. Because CoA is indispensable for energy production and biosynthetic pathways, pantothenate kinase activity sits at a metabolic control point that influences cell growth, proliferation and stress responses. In humans, pantothenate kinase activity is encoded by the PANK gene family. PANK1, PANK2 and PANK3 produce active enzymes, while PANK4 is a pseudo-pantothenate kinase that lacks robust catalytic activity under standard conditions. Despite its reduced activity, PANK4 has emerged as a regulator of skeletal muscle substrate metabolism and T-cell lipid synthesis, indicating non-catalytic or context-dependent roles. The importance of pantothenate kinase activity extends to disease: mutations in PANK2 cause pantothenate kinase-associated neurodegeneration (PKAN), and recent studies show that SGLT2 inhibitors activate pantothenate kinase in the human heart, linking this activity to cardiac metabolic remodeling. For researchers, GO:0004594 provides a precise functional annotation to study CoA homeostasis, metabolic reprogramming and therapeutic targeting. This article summarizes the definition, mechanism, key genes, regulation, disease relevance and experimental models for pantothenate kinase activity, with all factual claims supported by published literature [1-8].
pantothenate kinase activity At A Glance
| GO ID | GO:0004594 |
|---|---|
| GO term | pantothenate kinase activity |
| Ontology | molecular_function |
| Synonym | None listed in QuickGO |
| Major function | ATP-dependent phosphorylation of pantothenate to 4'-phosphopantothenate, the first and rate-limiting step in coenzyme A biosynthesis |
| Human genes | PANK1, PANK2, PANK3, PANK4 |
| Pathway context | Coenzyme A biosynthesis; acetyl-CoA metabolism; TCA cycle; fatty acid metabolism |
| Disease link | Pantothenate kinase-associated neurodegeneration (PKAN) due to PANK2 mutations; metabolic syndrome and cardiac metabolism |
| Substrate | Pantothenate (vitamin B5) and ATP |
| Product | 4'-Phosphopantothenate and ADP |
What Is GO:0004594?
Pantothenate kinase activity (GO:0004594) is the catalytic function that phosphorylates pantothenate to 4'-phosphopantothenate using ATP as the phosphate donor. This activity represents the committed and rate-limiting step of the coenzyme A biosynthetic pathway, and it is therefore a key determinant of intracellular CoA levels. The term is classified as a molecular function in the Gene Ontology, although it is often studied in the context of biological processes such as CoA metabolism and acetyl-CoA homeostasis.
Why Is pantothenate kinase activity Important in Cell Biology?
Pantothenate kinase activity is important because it controls the rate-limiting step of coenzyme A biosynthesis, thereby influencing virtually all metabolic pathways that require acetyl-CoA or other CoA thioesters, including the TCA cycle, fatty acid synthesis and oxidation, and protein acetylation. Dysregulation of this activity has been linked to neurodegeneration, metabolic syndrome, skeletal muscle metabolism and T-cell proliferation, making it a potential therapeutic target. Recent studies showing that SGLT2 inhibitors activate pantothenate kinase in the human heart further highlight its clinical relevance in cardiometabolic disease.
• Rate-limiting step in coenzyme A biosynthesis, controlling cellular CoA supply.
• Essential for energy metabolism via the TCA cycle and acetyl-CoA production.
• Regulates fatty acid synthesis and oxidation through CoA availability.
• PANK2 mutations cause pantothenate kinase-associated neurodegeneration (PKAN).
• PANK4 controls skeletal muscle substrate metabolism and T-cell lipid synthesis.
• SGLT2 inhibitors activate pantothenate kinase in the human heart, linking it to cardiac metabolic remodeling.
• Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome, implicating pantothenate phosphorylation in host metabolism.
• Pantothenamide-type inhibitors target pantothenate kinase, providing chemical tools and potential antimicrobials.
• PANK4 is a pseudo-pantothenate kinase, offering a model to study non-catalytic functions.
• Pantothenate kinase activity is a candidate target for metabolic and proliferative diseases.
Molecular Mechanism of pantothenate kinase activity
Substrate recognition and binding
In simple terms: The enzyme grabs pantothenate and ATP and holds them in the right position to react.
Pantothenate kinase binds pantothenate (vitamin B5) and ATP in its active site. The enzyme recognizes the pantothenate moiety through a conserved binding pocket, and ATP provides the phosphate group for the reaction. Structural and enzymological studies of pantothenamide inhibitors have revealed key interactions that define substrate specificity and guide inhibitor design.
Catalytic phosphorylation
In simple terms: The enzyme transfers a phosphate from ATP onto pantothenate, making 4'-phosphopantothenate.
The catalytic mechanism involves the transfer of the gamma-phosphate of ATP to the 4'-hydroxyl group of pantothenate, yielding 4'-phosphopantothenate and ADP. This phosphorylation is the first committed step in CoA biosynthesis and is rate-limiting, meaning its speed controls the overall flux through the pathway.
Role in coenzyme A biosynthesis
In simple terms: The product of this reaction is the starting material for making coenzyme A.
4'-Phosphopantothenate is subsequently converted through a series of enzymatic steps to coenzyme A. Because pantothenate kinase activity is rate-limiting, changes in its expression or activity directly affect intracellular CoA levels, which in turn influence acetyl-CoA-dependent processes such as the TCA cycle and fatty acid metabolism.
Isoform-specific features
In simple terms: Different PANK enzymes have different abilities; one of them, PANK4, is mostly inactive.
Human PANK1, PANK2 and PANK3 are active pantothenate kinases, whereas PANK4 is a pseudo-pantothenate kinase with markedly reduced catalytic activity. Despite this, PANK4 regulates skeletal muscle substrate metabolism and T-cell lipid synthesis, suggesting that it may act through protein-protein interactions or in specific metabolic contexts rather than through canonical phosphorylation.
Inhibition by pantothenamides
In simple terms: Synthetic molecules called pantothenamides can block the enzyme, which is useful for research and drug development.
Pantothenamide-type compounds act as inhibitors of pantothenate kinase by mimicking the substrate and interfering with catalysis. Structure-activity relationship studies have defined how modifications to the pantothenamide scaffold affect enzyme inhibition, providing chemical probes to study pantothenate kinase function and potential antimicrobial agents.
Key Genes Involved in GO:0004594 pantothenate kinase activity
The human pantothenate kinase family comprises four genes (PANK1-PANK4) that encode enzymes with distinct catalytic activities and tissue-specific roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PANK1 | Active pantothenate kinase; contributes to CoA biosynthesis | Metabolic regulation; potential target in metabolic disease |
| PANK2 | Active pantothenate kinase; mutations cause PKAN | Neurodegeneration; iron accumulation; therapeutic target |
| PANK3 | Active pantothenate kinase; broadly expressed | CoA homeostasis; drug discovery |
| PANK4 | Pseudo-pantothenate kinase; regulates muscle metabolism and T-cell lipid synthesis | Non-catalytic roles; skeletal muscle and immunometabolism |
| PANK1/PANK2/PANK3 | Catalyze the rate-limiting step of CoA biosynthesis | Core CoA pathway; metabolic engineering |
| PANK4 (muscle) | Controls substrate metabolism in skeletal muscle | Exercise physiology; insulin sensitivity |
| PANK4 (T cells) | Modulates CoA and glutaminolysis for lipid synthesis | T-cell proliferation; cancer immunology |
| PANK2 (heart) | Target of SGLT2 inhibitor-mediated activation | Cardiac metabolism; heart failure |
| PANK (gut) | Influenced by Bacteroides-derived pantothenic acid | Microbiome-host metabolic interactions |
| PANK (inhibitors) | Inhibited by pantothenamides | Antimicrobial and chemical biology |
| PANK1-4 (pan-family) | Maintain CoA pools for acetyl-CoA-dependent pathways | Metabolic reprogramming in cancer and diabetes |
| PANK2 (PKAN) | Loss-of-function mutations lead to neurodegeneration | Disease modeling; gene therapy |
| PANK4 (pseudo) | Lacks robust catalytic activity but has regulatory roles | Structure-function studies |
| PANK (therapeutic) | Target for metabolic and proliferative diseases | Drug development |
| PANK (SGLT2i) | Activated by SGLT2 inhibitors in heart | Cardioprotection; clinical pharmacology |
| PANK (microbiome) | Modulated by gut microbial pantothenic acid | Metabolic syndrome; probiotic approaches |
| PANK (T-cell) | Supports lipid synthesis for proliferation | Immunometabolism; autoimmune disease |
How Is pantothenate kinase activity Regulated?
Pantothenate kinase activity is regulated at multiple levels. At the transcriptional level, PANK genes respond to metabolic cues, and at the post-translational level, the enzymes can be modulated by feedback inhibition by CoA derivatives and by interacting proteins. Recent studies show that SGLT2 inhibitors activate pantothenate kinase in the human heart, indicating pharmacological regulation. In skeletal muscle, PANK4 controls substrate metabolism, suggesting that its activity or abundance is tuned to metabolic demand. In T cells, PANK4 modulates CoA and glutaminolysis to support lipid synthesis during proliferation, linking pantothenate kinase function to immune cell activation. Additionally, gut commensal Bacteroides-derived pantothenic acid can influence host pantothenate availability and thus indirectly affect pantothenate kinase activity.
pantothenate kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PANK2 | Pantothenate kinase-associated neurodegeneration (PKAN) | PANK2 knockout neurons; patient iPSC-derived neurons |
| PANK4 | Skeletal muscle substrate metabolism; T-cell proliferation | PANK4 knockout mice; T-cell-specific KO |
| PANK1/PANK3 | CoA homeostasis; metabolic disease | Liver-specific KO; overexpression models |
| PANK (heart) | SGLT2 inhibitor response; cardiac metabolism | Cardiomyocyte-specific KO; SGLT2i treatment |
| PANK (microbiome) | Metabolic syndrome | Germ-free mice colonized with Bacteroides; pantothenate supplementation |
Pantothenate kinase-associated neurodegeneration (PKAN)
Mutations in PANK2 cause pantothenate kinase-associated neurodegeneration (PKAN), a rare autosomal recessive disorder characterized by iron accumulation in the brain and progressive neurodegeneration. Loss of PANK2 activity impairs CoA biosynthesis, leading to metabolic stress and neuronal death. This establishes pantothenate kinase activity as directly linked to a human neurodegenerative disease.
Metabolic syndrome and gut microbiota
Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome in preclinical models, highlighting the role of pantothenate availability and its phosphorylation in host metabolic health. This suggests that pantothenate kinase activity in host tissues or microbiota may influence systemic metabolism and could be targeted for metabolic disorders.
Cardiac metabolism and SGLT2 inhibitors
SGLT2 inhibitors activate pantothenate kinase in the human heart, linking this activity to cardiac metabolic remodeling and potential cardioprotection. This finding positions pantothenate kinase as a downstream mediator of SGLT2 inhibitor effects in the heart, with implications for heart failure and diabetic cardiomyopathy.
Skeletal muscle metabolism and T-cell proliferation
PANK4 controls skeletal muscle substrate metabolism, and it also regulates lipid synthesis for T-cell proliferation by modulating CoA and glutaminolysis. These roles connect pantothenate kinase activity to exercise physiology, insulin sensitivity, and immune cell function, with potential relevance to diabetes, obesity, and autoimmune or inflammatory diseases.
From pantothenate kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PANK2 cause neurodegeneration? | PANK2 knockout mice or patient iPSC-derived neurons |
| How does PANK4 regulate muscle metabolism? | Skeletal muscle-specific PANK4 knockout mice |
| What is the role of PANK4 in T-cell proliferation? | T-cell-specific PANK4 knockout or overexpression |
| How do SGLT2 inhibitors affect cardiac pantothenate kinase? | Cardiomyocyte-specific PANK knockout with SGLT2i treatment |
| Can pantothenamide inhibitors block pantothenate kinase in vivo? | Xenograft or infection models treated with pantothenamides |
| Does gut microbiota-derived pantothenate affect host metabolism? | Germ-free mice colonized with Bacteroides; dietary pantothenate modulation |
How to Study the pantothenate kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Coupled enzyme assay | Pantothenate kinase catalytic activity | Kinetic studies; inhibitor screening |
| LC-MS metabolomics | CoA and intermediate levels | Metabolic flux; PANK4 function |
| CRISPR knockout | Loss-of-function phenotypes | Gene function in metabolism and disease |
| RNA-seq | Transcriptional changes upon PANK modulation | Pathway analysis; metabolic reprogramming |
| Western blot | Protein expression of PANK isoforms | Validation of KO or overexpression |
| Immunoprecipitation | Protein-protein interactions | Identifying PANK4 binding partners |
| X-ray crystallography | Three-dimensional structure of PANK | Inhibitor design |
| Seahorse assay | Mitochondrial respiration and glycolysis | Metabolic phenotype of PANK KO |
Enzymatic activity assays
Pantothenate kinase activity can be measured using coupled enzyme assays that monitor ADP production or 4'-phosphopantothenate formation. These assays are used to determine kinetic parameters and to test inhibitors such as pantothenamides.
Metabolomics and CoA measurement
Liquid chromatography-mass spectrometry (LC-MS) can quantify CoA and its intermediates, providing a readout of pantothenate kinase activity in cells and tissues. This approach has been used to link PANK4 function to CoA and glutaminolysis in T cells.
Genetic knockout and knockdown
CRISPR-Cas9 knockout or RNA interference of PANK genes in cell lines and animal models allows researchers to study loss-of-function phenotypes, such as altered muscle metabolism or impaired T-cell proliferation.
Structural biology and inhibitor design
X-ray crystallography and structure-activity relationship studies of pantothenamide inhibitors have elucidated the active site of pantothenate kinase and guided the development of chemical probes.
How CRISPR Can Be Used to Study GO:0004594 pantothenate kinase activity
Knockout
CRISPR-Cas9 knockout of PANK genes is used to abolish pantothenate kinase activity and study downstream effects on CoA levels, metabolism and cell proliferation. For example, PANK4 knockout in skeletal muscle cells reveals its role in substrate metabolism, and PANK2 knockout models mimic PKAN neurodegeneration.
Point Mutation
Point mutations can be introduced into PANK genes to model disease-associated variants, such as those found in PKAN patients, or to dissect catalytic residues. These models help distinguish between catalytic and non-catalytic functions of PANK proteins.
Knock-in
Knock-in of tagged PANK alleles (e.g., FLAG or GFP) allows endogenous expression and localization studies. This approach is useful for tracking PANK4, which has regulatory roles independent of its catalytic activity.
Overexpression
Overexpression of PANK1, PANK2 or PANK3 increases pantothenate kinase activity and CoA levels, enabling gain-of-function studies in metabolic and proliferative contexts, such as T-cell activation or cardiac metabolism.
How EDITGENE Supports pantothenate kinase activity Research
Researchers studying pantothenate kinase activity-related genes often need to determine whether a candidate gene is causally involved in CoA metabolism, metabolic disease or neurodegeneration. EDITGENE provides CRISPR-based cell models and screening services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for pantothenate kinase activity research.
Frequently Asked Questions About pantothenate kinase activity
What is pantothenate kinase activity?
Pantothenate kinase activity (GO:0004594) is the enzymatic function that phosphorylates pantothenate to 4'-phosphopantothenate, the first and rate-limiting step in coenzyme A biosynthesis.
What genes are involved in pantothenate kinase activity?
The human genes are PANK1, PANK2, PANK3 and PANK4; PANK1-3 encode active enzymes, while PANK4 is a pseudo-pantothenate kinase.
What is the role of PANK4?
PANK4 is a pseudo-pantothenate kinase that regulates skeletal muscle substrate metabolism and T-cell lipid synthesis by modulating CoA and glutaminolysis.
How is pantothenate kinase activity regulated?
It is regulated by feedback inhibition, transcriptional control, and pharmacological agents such as SGLT2 inhibitors, which activate it in the human heart.
What diseases are linked to pantothenate kinase activity?
Mutations in PANK2 cause pantothenate kinase-associated neurodegeneration (PKAN), and the activity is implicated in metabolic syndrome and cardiac metabolism.
What is the substrate of pantothenate kinase?
The substrate is pantothenate (vitamin B5), which is phosphorylated using ATP.
What is the product of pantothenate kinase activity?
The product is 4'-phosphopantothenate, which is further converted to coenzyme A.
Can pantothenate kinase be inhibited?
Yes, pantothenamide-type compounds inhibit pantothenate kinase and are used as chemical probes and potential antimicrobials.
How do SGLT2 inhibitors affect pantothenate kinase?
SGLT2 inhibitors activate pantothenate kinase in the human heart, linking the enzyme to cardiac metabolic remodeling.
What model systems are used to study pantothenate kinase activity?
Common models include CRISPR knockout cell lines and mice, patient iPSC-derived neurons, and enzymatic assays with recombinant PANK proteins.
Conclusion
Pantothenate kinase activity (GO:0004594) is a central metabolic function that controls coenzyme A biosynthesis and influences diverse physiological processes, from neurodegeneration to cardiac and immune metabolism [1-8]. Its four human isoforms, particularly the pseudo-kinase PANK4, have distinct and context-dependent roles that are actively being unraveled. Understanding this activity offers opportunities for therapeutic intervention in metabolic and neurodegenerative diseases.
References
- 1. Luo Z et al.. 2026. Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome.. Cell Host Microbe 34(9):1764-1778.e8 PMID: 42385714
- 2. Forelli N et al.. 2026. SGLT2 inhibitors activate pantothenate kinase in the human heart.. Science 393(6814):895-902 PMID: 42658934
- 3. Miranda-Cervantes A et al.. 2025. Pantothenate kinase 4 controls skeletal muscle substrate metabolism.. Nat Commun 16(1):345 PMID: 39746949
- 4. Forelli N et al.. 2024. SGLT2 inhibitors activate pantothenate kinase in the human heart.. bioRxiv PMID: 39091820
- 5. Hwang JR et al.. 2025. Pantothenate kinase 4 controls lipid synthesis for T-cell proliferation by modulating coenzyme A and glutaminolysis.. Signal Transduct Target Ther 10(1):302 PMID: 40962808
- 6. Zhang X et al.. 2025. Targeting pantothenate kinases in human diseases: Biochemistry and pharmacotherapy.. Biochem Pharmacol 242(Pt 2):117207 PMID: 40754168
- 7. Yao J et al.. 2019. Human pantothenate kinase 4 is a pseudo-pantothenate kinase.. Protein Sci 28(6):1031-1047 PMID: 30927326
- 8. Virga KG et al.. 2006. Structure-activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors.. Bioorg Med Chem 14(4):1007-20 PMID: 16213731
